Rexam gains Mexican packaging plant
This article was originally published in The Rose Sheet
Executive Summary
UK-based firm with vision "to be the leading global consumer packaging company" - it currently is No. 2 - assumes ownership of plastic packaging injection and extrusion blow-molded manufacturing plant in Tlalnepantla, Mexico City with purchase of remaining 50% interest in joint venture between it and Pavisa Industries. Consistent with the company's goal of building its presence in emerging markets, "Rexam will be utilizing the plant to exploit growth for plastic packaging across the healthcare, closures and personal-care industries in the Mexico and Latin American markets," according to Feb. 24 announcement. The Mexico City facility has more than 300 employees, Rexam says, and produces plastic for the pharmaceutical and diagnostic industries as well as for firms needing cases for lipsticks, mascaras and compacts and dispensing solutions for perfumes, lotions and foams. Firm reported Feb. 19 that its fiscal 2008 full-year sales totaled $6.54 bil., up 28% from 2007 including the benefit of recent acquisitions and foreign currency exchange
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.